CLC Number:
| [1] Eroglu Z, Tagawa T, Somlo G. Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer[J]. Oncol, 2014, 19(2): 135-150. [2] Swain SM, Miles D, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer(CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study[J]. Lancet Oncol, 2020, 21(4): 519-530. [3] Ma F, Li Q, Chen S, et al. Phase I study and biomarker analysis of pyrotinib, a novel irreversible Pan-ErbB receptor tyrosine kinase inhibitor, in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer[J]. J Clin Oncol, 2017, 35(27): 3105-3112. [4] Ma F, Ouyang QC, Li W, et al. Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab: a randomized, phase II study[J]. J Clin Oncol, 2019, 37(29): 2610-2619. [5] 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2019年版)[J]. 中国癌症杂志, 2019, 29(8): 609-680. [6] Rimawi MF, Schiff R, Osborne CK. Targeting HER2 for the treatment of breast cancer[J]. Annu Rev Med, 2015, 66: 111-128. doi:10.1146/annurev-med-042513-015127. [7] Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis[J]. Oncogene, 2007, 26(45): 6469-6487. [8] Wilson FR, Coombes ME, Brezden-Masley C, et al. Herceptin®(trastuzumab)in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis[J]. Syst Rev, 2018, 7(1): 191. doi:10.1186/s13643-018-0854-y. [9] Goutsouliak K, Veeraraghavan J, Sethunath V, et al. Towards personalized treatment for early stage HER2-positive breast cancer[J]. Nat Rev Clin Oncol, 2020, 17(4): 233-250. [10] Llombart-Cussac A, Cortés J, Paré L, et al. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer(PAMELA): an open-label, single-group, multicentre, phase 2 trial[J]. Lancet Oncol, 2017, 18(4): 545-554. [11] 宋国红, 李惠平, 邸立军, 等. 真实世界吡咯替尼治疗HER2阳性转移性乳腺癌的疗效及安全性[J]. 北京大学学报(医学版), 2020, 52(2): 254-260. SONG Guohong, LI Huiping, DI Lijun, et al. Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice[J]. Journal of Peking University(Health Sciences), 2020, 52(2): 254-260. [12] 房文通, 顾艳宏. 伴有合并症的结直肠癌治疗的药物选择[J]. 中华结直肠疾病电子杂志, 2018, 7(5): 420-430. FANG Wentong, GU Yanhong. Medication options for colorectal cancer with complications[J]. Chinese Journal of Colorectal Diseases, 2018, 7(5): 420-430. |
| [1] | ZHOU Bin, JIANG Zhi-long, GENG Zhong-ze, CAO Bing, PENG Zhi-xiang. A feasibility analysis of trans-umbilical single-port laparoscopic cholecystectomy: Report of 48 cases [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(11): 105-107. |
| [2] | . [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(9): 163-164. |
|
||
